Journal of Medical Toxicology (2018) 14:257–260 https://doi.org/10.1007/s13181-018-0666-4 1 1 1 1 Melissa H. Gittinger & Joseph Edward Carpenter & Camille Ashley Dunkley & Brian Patrick Murray & 1 1 Brent Morgan & Ziad Kazzi Received: 11 May 2018 / Accepted: 15 May 2018 / Published online: 30 May 2018 # American College of Medical Toxicology 2018 . . . . . Keywords Buprenorphine Naltrexone Opioid use disorder Radioactive iodine Thyroid cancer Opium lead toxicity Article Title Methods Lee JD, Nunes Jr. EV, Novo P, et al.: Comparative effective- This was a 24-week, multicenter, open-label, and randomized trial ness of extended-release naltrexone versus buprenorphine- including subjects who had been admitted to inpatient detoxifica- naloxone for opioid relapse prevention (X:BOT): a tion centers. Subjects were randomized to receive ~ 380 mg of multicentre, open-label, randomised controlled trial. Lancet XR-NTX every 28 days or daily doses of 8–24 mg BUP-NX, 2018;391:309–18. supplied weekly. Those randomized to the XR-NTX group were required to have an opioid-negative urine screen and negative naloxone challenge before initiating treatment. Withdrawal symp- Background toms were managed according to usual care at each study site. After discharge from the inpatient center, subjects had weekly Detoxification and counseling-only aftercare have
Journal of Medical Toxicology – Springer Journals
Published: May 30, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera